ReiThera, the Italian-based CDMO offering best-in-class process development and GMP manufacturing services for viral vectors today announces six oral presentations at the European Society of Gene & Cell Therapy 31st Annual Meeting (ESGCT), to be held October 22-25 in Rome.
During ESGCT Reithera’s team will be available to share details about:
- ReiCell-AAV: HEK293-derived cell line for AAV manufacture in suspension
- The GRAd platform: gorilla derived adenoviral vector platform for genetic vaccine
- The MVA platform: from MVA vector construction to GMP in adhesion and suspension
- The HSV vector: an established process in GMP grade-B area
- One-stop-shop: GMP DS & DP production and release from 2L to 2000L STR Bioreactor
“As CEO of ReiThera, I believe that participating in the ESGCT conference is crucial for fostering collaboration and innovation in the field of gene and cell therapy, allowing us to share our cutting-edge research and advancements with the scientific community and contribute to shaping the future of healthcare.” – Stefano Colloca, CEO of ReiThera.
Come and join us at booth B14/16 in La Nuvola, EUR!
Schedule a meeting in advance: businessdevelopment@reithera.com
Oral Presentations details:
Title: GRAd as vaccine platform for COVID-19, HIV, and global health
Speaker: Angelo Raggioli
Angelo will be presenting the latest update on how the GRAd platform can be customized to deliver clinical efficacy an antinfective vaccine and immuno-oncology. In particular, initial data on the GRAd-HIV vaccine will be shared. GRAd-HIV is a program run in collaboration with IAVI & the Ragon Institute and it is supported by the Bill and Melinda Foundation.
Presentation Date/Time: Wed. 23rd 8.30-10.30
Session title: SESSION 3c: Infectious Diseases / Vaccines
Session Room: Meeting Room 2 ∙ PARALLEL
———
Title: Optimization of the two-plasmid system for AAV production
Speaker: Michela Gentile
Michela will be presenting the results of a dual plasmid system to produced AAV by using Stirred Tank bioreactor. Data on the proprietary ReiCell-AAV cell line platform will be also presented.
Presentation Date/Time: Wed. 23rd 13:30-14:30
Session title: LUNCHTIME SYMPOSIUM: PlasmidFactory – A spotlight on plasmid and minicircle DNA starting materials for AAV vectors
Session Room: Meeting Room 1
———
Title: How to increase AVV productivity in ReiCell-AAV by combining Virica’s VSA Technology
Presentation date: Thurs 24th 11:00-11:30
ReiThera & Virica will be presenting the latest results on AAV productivity improvement obtained by combining Virica’s VSA elements and ReiThera’s proprietary ReiCell-AAV cell line.
———
Title: An innovative and scalable chromatographic purification approach for Modified Vaccinia Ankara (MVA) manufacturing process
Speaker: Andrea Valeria Canosa
Andrea Valeria will be presenting the latest results on MVA vector downstream which includes a scalable chromatographic step complying with sterility condition typical of non filtrable vector produced in a GMP class B area.
Presentation Date/Time: Wed. 23th 13:30 -15:00
Session title: POSTER SESSION II
Session Room: Concourse Level 1 and Mezzanine Concourse
Poster number: P0452
———
Title: Development of a reverse phase chromatography assays for quantification of detergent residuals in vaccine purification process
Speaker: Andrea di Santo
Andrea will be presenting the latest data on HPLC reverse phase chromatography assays targeting the residuals titer like Domiphen Bromide and Polysorbate 20 & 80 during manufacturing and Drug Substance release.
Presentation Date/Time: Tues. 22nd 19:30-21:00
Session title: POSTER SESSION I
Session Room: Concourse Level 1 and Mezzanine Concourse
Poster number: P0455
———
Title: From bench to dose: building a robust and scalable cGMP manufacturing process for non-replicative Herpes Simplex Virus 1 (nrHSV-1) vector as a powerful gene therapy platform
Speaker: Giuseppina Miselli
Giuseppina will be presenting the manufacturing platform developed for HSV GMP production: an effective approach to deliver in a reduced timeframe Drug Substance and Drug Product for clinical use. The process was performed in accordance with sterility compliance typical of a non filtrable vector produced in GMP Class B area.
Presentation Date/Time: Thurs. 24th 14:00-15:30
Session title: POSTER SESSION III
Session Room: Concourse Level 1 and Mezzanine Concourse
Final abstract number: P1043
———
Title: Upstream process intensification for a gorilla derived adenoviral (GRAd) vector by using a perfusion system
Speaker: Alessia Noto
Alessia will be presenting data related the manufacturing process platform of a GRAd based vector by using cell density intensification by perfusion leading to the improvement of volumetric productivity
Presentation Date/Time: Thurs. 22nd 19:30-21:00
Session title: POSTER SESSION I
Session Room: Concourse Level 1 and Mezzanine Concourse
Poster number: P0453
———
Title: Enhanced thermostability of a gorilla-derived adenoviral (grad) vector via e4 region chimerism
Speaker: Michela Gentile
Michela will be presenting additional data on the GRAd platform robustness and the enhanced stability improvement at +4°C and +37°C: a critical advantage in the global vaccine distribution.
Presentation Date/Time: Wed. 23th 13:30 -15:00
Session title: POSTER SESSION II
Session Room: Concourse Level 1 and Mezzanine Concourse
Poster number: P0454
———
Title: A simplified AAV infectivity assay enhances efficiency and throughput
Speaker: Angelo Raggioli
Angelo will be presenting a shorter TCID50 methodology; a faster approach to investigate vector quality during process development.
Presentation Date/Time: Wed. 23th 13:30 -15:00
Session title: POSTER SESSION II
Session Room: Concourse Level 1 and Mezzanine Concourse
Poster number: P0018